CRISPR/Cas9 Shows Promise for Patients with LCA

Mark E. Pennesi, MD, PHD

Show Description +

Mark E. Pennesi, MD, PHD, speaks about the Brilliance phase 1/2 trial of patients with Leber Congenital Amaurosis—the first human trial using CRISPR/Cas9 gene editing.

Posted: 10/18/2022

Keywords:

Leber Congenital Amaurosis

•

retina-meeting-recap

•

Clinical Trials

•

gene editing

•

Gene Therapy

•

CRISPR/Cas9

Up Next

Type 1 Neovascularization or CSC?

Dinah Zur, MD; and Anat Loewenstein, MD, MHA

A Word From Euretina's President

Alistair Laidlaw, MBBS, MD

Gearing Up for a GA Therapy

Kourous A. Rezaei, MD; and Anat Loewenstein, MD, MHA

Using AI for DR Screening in India

S. Natarajan, MBBS, DO, FICO (UK), FVRS; and Andrzej Grzybowski, MD, PhD, MBA

Steps to Achieving the Impossible in DR Management

Sobha Sivaprasad, MBBS, MS, DM, FRCS, FRCOphth

The Coming Shift in AMD Care

Anat Loewenstein, MD, MHA; and Alistair Laidlaw, MBBS, MD

Treating Traumatic Aphakia and Aniridia

Matteo Forlini, MD; and Mario R. Romano, MD, PhD

Back to All Videos

CRISPR/Cas9 Shows Promise for Patients with LCA

Mark E. Pennesi, MD, PHD

Mark E. Pennesi, MD, PHD, speaks about the Brilliance phase 1/2 trial of patients with Leber Congenital Amaurosis—the first human trial using CRISPR/Cas9 gene editing.

Posted: 10/18/2022

Keywords:

Leber Congenital Amaurosis

•

retina-meeting-recap

•

Clinical Trials

•

gene editing

•

Gene Therapy

•

CRISPR/Cas9

Please log in to leave a comment.

Meeting Coverage:

EURETINA Congress

CRISPR/Cas9 Shows Promise for Patients with LCA

Up Next

CRISPR/Cas9 Shows Promise for Patients with LCA

More From EURETINA: 2022 Coverage